title: Enzyme replacement therapy for Anderson-Fabry disease.
abstract: BACKGROUND
  Anderson-Fabry disease is an X-linked defect of glycosphingolipid metabolism. Progressive renal insufficiency is a major source of morbidity, additional complications result from cardio- and cerebro-vascular involvement. Survival is reduced among affected males and symptomatic female carriers.
  
  
  OBJECTIVE
  To evaluate the effectiveness and safety of enzyme replacement therapy compared to other interventions, placebo or no interventions, for treating Anderson-Fabry disease.
  
  
  METHODS
  We searched 'Clinical Trials' on The Cochrane Library, MEDLINE, EMBASE, LILACS and the Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register (date of the most recent search: 07 April 2010).
  
  
  METHODS
  Randomized controlled trials of agalsidase alfa or beta in participants diagnosed with Anderson-Fabry disease.
  
  
  METHODS
  Two authors selected relevant trials, assessed methodological quality and extracted data.
  
  
  RESULTS
  Five studies comparing either agalsidase alfa or beta in 187 participants fulfilled the selection criteria.Both trials comparing agalsidase alfa to placebo reported on globotriaosylceramide concentration in plasma and tissue; aggregate results were non-significant. One study reported pain scores, there was a statistically significant improvement for participants receiving treatment at up to three months, mean difference -2.10 (95% confidence interval (CI) -3.79 to -0.41); at up to five months, mean difference -1.90 (95% CI -3.65 to -0.15); and at up to six months, mean difference -2.00 (95% CI -3.66 to -0.34). There was a significant difference in pain-related quality of life at over five months and up to six months, mean difference -2.10 (95% CI -3.92 to -0.28) but not at other time-points. Neither study reported deaths.One of the three trials comparing agalsidase beta to placebo reported on globotriaosylceramide concentration in plasma and tissue and showed significant improvement: kidney, mean difference -1.70 (95% CI -2.09 to -1.31); heart, mean difference -0.90 (95% CI -1.18 to -0.62); and composite results (renal, cardiac, and cerebrovascular complications and death), mean difference -4.80 (95% CI -5.45 to -4.15). There was no significant difference between groups for death; no studies reported on pain.
  
  
  CONCLUSIONS
  Five small, poor quality randomised controlled trials provide no robust evidence for use of either agalsidase alfa and beta to treat Anderson-Fabry disease.
authors.affiliation: Department of Surgery, St. Joseph's Healthcare Hamilton, McMaster University, 50 Charlton Avenue East, Hamilton, ON, Canada, L8N 4A6.
authors.forename: Regina P
authors.initials: RP
authors.lastname: El Dib
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Pastores
mesh_terms: D000795:Fabry Disease / Q000188:drug therapy* / Q000201:enzymology; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000008:administration & dosage*; D008297:Male; D010147:Pain Measurement; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D013997:Time Factors; D014281:Trihexosylceramides / Q000097:blood; D000519:alpha-Galactosidase / Q000008:administration & dosage*
chemical_list: D007527:Isoenzymes; D011994:Recombinant Proteins; D014281:Trihexosylceramides; C000627036:agalsidase alfa; C018549:globotriaosylceramide; D000519:alpha-Galactosidase; C459420:agalsidase beta